The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study

The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study

Immune-related adverse events (irAEs) of immunotherapy would lead to the temporary or permanent discontinuation of immune checkpoint inhibitors (ICIs). Among them, checkpoint inhibitor pneumonitis (CIP) is a potentially life-threatening irAE. This study aimed to identify the differences between pati...

Full description

Bibliographic Details
Main Authors:	Hui Huang, Ruxuan Chen, Yan Xu, Nan Fang, Chi Shao, Kai Xu, Mengzhao Wang
Format:	Article
Language:	English
Published:	MDPI AG 2024-01-01
Series:	Journal of Clinical Medicine
Subjects:	immune-related adverse events checkpoint inhibitor pneumonitis severity grade prognosis
Online Access:	https://www.mdpi.com/2077-0383/13/1/255

Similar Items

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor
by: Hanping WANG, et al.
Published: (2019-10-01)

Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
by: Wenxian Wang, et al.
Published: (2022-12-01)

Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer
by: Xiaotong Lu, et al.
Published: (2022-06-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
by: CHEN Shuangqing, et al.
Published: (2022-10-01)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
by: Chuzi S, et al.
Published: (2017-06-01)

Epidemiological analysis of real-world immune checkpoint inhibitor-related pneumonitis in Chinese patients with lung cancer
by: WU Jianhui, CHU Xiangling, WANG Liqiang, LIN Xinqing, XIE Xiaohong, XIE Mengqing, ZHAO Jing, DENG Haiyi, YANG Yilin, QIU Guihuan, ZHOU Maolin, SUN Ni, LI Ru, CHEN Ying, DENG Jiaxi, ZENG Chen, PAN Bolin, QIN Yinyin, LIU Ming, SU Chunxia, ZHOU Chengzhi
Published: (2022-06-01)

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition
by: Kristine E. Mayer, et al.
Published: (2023-06-01)

Comparison of pneumonitis risk between immunotherapy alone and in combination with chemotherapy: an observational, retrospective pharmacovigilance study
by: Huixia Li, et al.
Published: (2023-04-01)

Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
by: Yuxuan Hao, et al.
Published: (2022-08-01)

Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
by: Kuan-Chang Lai, et al.
Published: (2022-08-01)

Association of Clinical and Radiological Features with Disease Severity of Symptomatic Immune Checkpoint Inhibitor-Related Pneumonitis
by: Qian Zhang, et al.
Published: (2023-02-01)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
by: Anca Bobircă, et al.
Published: (2021-06-01)

Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease
by: Zhu Zeng, et al.
Published: (2022-12-01)

Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
by: Kang Miao, et al.
Published: (2021-08-01)

Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
by: Xiaoyan Si, et al.
Published: (2023-07-01)

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor–related pneumonitis
by: Chengzhi Zhou, et al.
Published: (2022-07-01)

Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation
by: Shicong Zhu, et al.
Published: (2020-09-01)

Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis
by: Yanlin Li, et al.
Published: (2022-08-01)

Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
by: Mei-Xi Lin, et al.
Published: (2024-02-01)

The CURB65 score predicted 180-day mortality of non-small cell lung carcinoma patients with immune checkpoint inhibitor-associated pneumonitis: A pilot retrospective analysis
by: Fen Lan, et al.
Published: (2022-08-01)

Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer
by: Xinqing Lin, et al.
Published: (2021-07-01)

Development and validation of a nomogram for predicting immune‐related pneumonitis after sintilimab treatment
by: Baohui Hong, et al.
Published: (2024-02-01)

Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications
by: Sumeet Hindocha, et al.
Published: (2021-11-01)

Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report
by: Yuan Cheng, et al.
Published: (2022-07-01)

Role of Infliximab in Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Kathryn A. Lai, et al.
Published: (2020-11-01)

Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
by: Jianping Bi, et al.
Published: (2022-01-01)

Case report: Checkpoint inhibitor pneumonitis with positive anti-melanoma differentiation-associated gene 5 antibodies in a patient with lung cancer
by: Siqi Pan, et al.
Published: (2024-01-01)

Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning
by: Li Gong, et al.
Published: (2023-06-01)

Advances in CT features and radiomics of checkpoint inhibitor-related pneumonitis: A short review
by: Jie Huang, et al.
Published: (2023-01-01)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
by: Xinqing Lin, et al.
Published: (2022-01-01)

Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer
by: Qingtao Qiu, et al.
Published: (2022-04-01)

Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors
by: Yasuki Uchida, et al.
Published: (2022-05-01)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
by: Joshua E. Reuss, MD, et al.
Published: (2021-10-01)

A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
by: Dorthe Yakymenko, et al.
Published: (2023-01-01)

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
by: Qiang Su, et al.
Published: (2019-02-01)

Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
by: Jianqiong Yin, et al.
Published: (2022-04-01)

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature
by: Xiuju Liang, et al.
Published: (2019-12-01)

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab
by: Rongmao Gao, et al.
Published: (2023-06-01)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
by: Min Wang, et al.
Published: (2022-02-01)